Myelofibrosis, JAK2 inhibitors and erythropoiesis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Distinct stem cell identities converge into shared erythroid stress in ERCC6L2 disease and Shwachman-Diamond syndrome.HemaSphere · 2026
   Article
2. Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib.Cancers · 2024
   Review
3. A Comprehensive Overview of Globally Approved JAK Inhibitors.Pharmaceutics · 2022
   Review
4. Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies.HemaSphere · 2017
   Review
5. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.Blood · 2017
   Article
6. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.Experimental hematology · 2016
   Article
7. The European Hematology Association Roadmap for European Hematology Research: a consensus document.Haematologica · 2016
   Article
8. JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice.Journal of cellular and molecular medicine · 2015
   Article
9. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.Leukemia · 2014
   Article
10. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis.Leukemia · 2013
    Article

Corrections and comments

• Comment on
  Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.2013

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as